Efficacy of fimasartan/hydrochlorothiazide combination in hypertensive patients inadequately controlled by fimasartan monotherapy

Moo Yong Rhee, Sang Hong Baek, Weon Kim, Chang Gyu Park, Seung Woo Park, Byung Hee Oh, Sang Hyun Kim, Jae Joong Kim, Joon Han Shin, Byung Su Yoo, Se Joong Rim, Jong Won Ha, Joon Hyung Doh, Youngkeun Ahn, Jei Keon Chae, Jeong Bae Park, Soon Kil Kim, Cheol Ho Kim

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: The study reported here compared the blood pressure (BP)-lowering efficacy of fimasartan alone with that of fimasartan/hydrochlorothiazide (HCTZ) combination in patients whose BP goal was not achieved after 4 weeks of treatment with once-daily fimasartan 60 mg. Methods: Patients with sitting diastolic blood pressure (siDBP) ≥90 mmHg with 4 weeks of once-daily fimasartan 60 mg were randomly assigned to receive either once-daily fimasartan 60 mg/HCTZ 12.5 mg or fimasartan 60 mg for 4 weeks. After 4 weeks, the dose was increased from fimasartan 60 mg/HCTZ 12.5 mg to fimasartan 120 mg/HCTZ 12.5 mg or from fimasartan 60 mg to fimasartan 120 mg if siDBP was ≥90 mmHg. Results: Of the 263 randomized patients, 256 patients who had available efficacy data were analyzed. The fimasartan/HCTZ treatment group showed a greater reduction of siDBP compared to the fimasartan treatment group at Week 4 (6.88±8.10 mmHg vs 3.38±7.33, P=0.0008), and the effect persisted at Week 8 (8.67±9.39 mmHg vs 5.02±8.27 mmHg, P=0.0023). Reduction of sitting systolic BP in the fimasartan/HCTZ treatment group was also greater than that in the fimasartan treatment group (at Week 4, 10.50±13.76 mmHg vs 5.75±12.18 mmHg, P=0.0069 and, at Week 8, 13.45±15.15 mmHg vs 6.84±13.57 mmHg, P=0.0007). The proportion of patients who achieved a reduction of siDBP ≥10 mmHg from baseline and/or a mean siDBP <90 mmHg after 4 weeks of treatment was higher in the fimasartan/HCTZ treatment group than in the fimasartan treatment group (53.6% vs 39.8%, P=0.0359). The overall incidence of adverse drug reaction was 11.79% with no significant difference between the treatment groups. Conclusion: The combination treatment of fimasartan and HCTZ achieved better BP control than fimasartan monotherapy, and had comparable safety and tolerance to fimasartan monotherapy.

Original languageEnglish
Pages (from-to)2847-2854
Number of pages8
JournalDrug Design, Development and Therapy
Volume9
DOIs
Publication statusPublished - 2015 Jun 2

Fingerprint

Hydrochlorothiazide
Blood Pressure
fimasartan
Therapeutics

Keywords

  • Angiotensin II type 1 receptor
  • Angiotensin-converting enzyme inhibitor
  • Angiotensin-receptor blocker
  • Antihypertensive
  • Blood pressure
  • Renin–angiotensin–aldosterone system inhibitor

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science
  • Drug Discovery

Cite this

Efficacy of fimasartan/hydrochlorothiazide combination in hypertensive patients inadequately controlled by fimasartan monotherapy. / Rhee, Moo Yong; Baek, Sang Hong; Kim, Weon; Park, Chang Gyu; Park, Seung Woo; Oh, Byung Hee; Kim, Sang Hyun; Kim, Jae Joong; Shin, Joon Han; Yoo, Byung Su; Rim, Se Joong; Ha, Jong Won; Doh, Joon Hyung; Ahn, Youngkeun; Chae, Jei Keon; Park, Jeong Bae; Kim, Soon Kil; Kim, Cheol Ho.

In: Drug Design, Development and Therapy, Vol. 9, 02.06.2015, p. 2847-2854.

Research output: Contribution to journalArticle

Rhee, MY, Baek, SH, Kim, W, Park, CG, Park, SW, Oh, BH, Kim, SH, Kim, JJ, Shin, JH, Yoo, BS, Rim, SJ, Ha, JW, Doh, JH, Ahn, Y, Chae, JK, Park, JB, Kim, SK & Kim, CH 2015, 'Efficacy of fimasartan/hydrochlorothiazide combination in hypertensive patients inadequately controlled by fimasartan monotherapy', Drug Design, Development and Therapy, vol. 9, pp. 2847-2854. https://doi.org/10.2147/DDDT.S82098
Rhee, Moo Yong ; Baek, Sang Hong ; Kim, Weon ; Park, Chang Gyu ; Park, Seung Woo ; Oh, Byung Hee ; Kim, Sang Hyun ; Kim, Jae Joong ; Shin, Joon Han ; Yoo, Byung Su ; Rim, Se Joong ; Ha, Jong Won ; Doh, Joon Hyung ; Ahn, Youngkeun ; Chae, Jei Keon ; Park, Jeong Bae ; Kim, Soon Kil ; Kim, Cheol Ho. / Efficacy of fimasartan/hydrochlorothiazide combination in hypertensive patients inadequately controlled by fimasartan monotherapy. In: Drug Design, Development and Therapy. 2015 ; Vol. 9. pp. 2847-2854.
@article{a18f291ef83d4876ac1f8328797b6837,
title = "Efficacy of fimasartan/hydrochlorothiazide combination in hypertensive patients inadequately controlled by fimasartan monotherapy",
abstract = "Background: The study reported here compared the blood pressure (BP)-lowering efficacy of fimasartan alone with that of fimasartan/hydrochlorothiazide (HCTZ) combination in patients whose BP goal was not achieved after 4 weeks of treatment with once-daily fimasartan 60 mg. Methods: Patients with sitting diastolic blood pressure (siDBP) ≥90 mmHg with 4 weeks of once-daily fimasartan 60 mg were randomly assigned to receive either once-daily fimasartan 60 mg/HCTZ 12.5 mg or fimasartan 60 mg for 4 weeks. After 4 weeks, the dose was increased from fimasartan 60 mg/HCTZ 12.5 mg to fimasartan 120 mg/HCTZ 12.5 mg or from fimasartan 60 mg to fimasartan 120 mg if siDBP was ≥90 mmHg. Results: Of the 263 randomized patients, 256 patients who had available efficacy data were analyzed. The fimasartan/HCTZ treatment group showed a greater reduction of siDBP compared to the fimasartan treatment group at Week 4 (6.88±8.10 mmHg vs 3.38±7.33, P=0.0008), and the effect persisted at Week 8 (8.67±9.39 mmHg vs 5.02±8.27 mmHg, P=0.0023). Reduction of sitting systolic BP in the fimasartan/HCTZ treatment group was also greater than that in the fimasartan treatment group (at Week 4, 10.50±13.76 mmHg vs 5.75±12.18 mmHg, P=0.0069 and, at Week 8, 13.45±15.15 mmHg vs 6.84±13.57 mmHg, P=0.0007). The proportion of patients who achieved a reduction of siDBP ≥10 mmHg from baseline and/or a mean siDBP <90 mmHg after 4 weeks of treatment was higher in the fimasartan/HCTZ treatment group than in the fimasartan treatment group (53.6{\%} vs 39.8{\%}, P=0.0359). The overall incidence of adverse drug reaction was 11.79{\%} with no significant difference between the treatment groups. Conclusion: The combination treatment of fimasartan and HCTZ achieved better BP control than fimasartan monotherapy, and had comparable safety and tolerance to fimasartan monotherapy.",
keywords = "Angiotensin II type 1 receptor, Angiotensin-converting enzyme inhibitor, Angiotensin-receptor blocker, Antihypertensive, Blood pressure, Renin–angiotensin–aldosterone system inhibitor",
author = "Rhee, {Moo Yong} and Baek, {Sang Hong} and Weon Kim and Park, {Chang Gyu} and Park, {Seung Woo} and Oh, {Byung Hee} and Kim, {Sang Hyun} and Kim, {Jae Joong} and Shin, {Joon Han} and Yoo, {Byung Su} and Rim, {Se Joong} and Ha, {Jong Won} and Doh, {Joon Hyung} and Youngkeun Ahn and Chae, {Jei Keon} and Park, {Jeong Bae} and Kim, {Soon Kil} and Kim, {Cheol Ho}",
year = "2015",
month = "6",
day = "2",
doi = "10.2147/DDDT.S82098",
language = "English",
volume = "9",
pages = "2847--2854",
journal = "Drug Design, Development and Therapy",
issn = "1177-8881",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Efficacy of fimasartan/hydrochlorothiazide combination in hypertensive patients inadequately controlled by fimasartan monotherapy

AU - Rhee, Moo Yong

AU - Baek, Sang Hong

AU - Kim, Weon

AU - Park, Chang Gyu

AU - Park, Seung Woo

AU - Oh, Byung Hee

AU - Kim, Sang Hyun

AU - Kim, Jae Joong

AU - Shin, Joon Han

AU - Yoo, Byung Su

AU - Rim, Se Joong

AU - Ha, Jong Won

AU - Doh, Joon Hyung

AU - Ahn, Youngkeun

AU - Chae, Jei Keon

AU - Park, Jeong Bae

AU - Kim, Soon Kil

AU - Kim, Cheol Ho

PY - 2015/6/2

Y1 - 2015/6/2

N2 - Background: The study reported here compared the blood pressure (BP)-lowering efficacy of fimasartan alone with that of fimasartan/hydrochlorothiazide (HCTZ) combination in patients whose BP goal was not achieved after 4 weeks of treatment with once-daily fimasartan 60 mg. Methods: Patients with sitting diastolic blood pressure (siDBP) ≥90 mmHg with 4 weeks of once-daily fimasartan 60 mg were randomly assigned to receive either once-daily fimasartan 60 mg/HCTZ 12.5 mg or fimasartan 60 mg for 4 weeks. After 4 weeks, the dose was increased from fimasartan 60 mg/HCTZ 12.5 mg to fimasartan 120 mg/HCTZ 12.5 mg or from fimasartan 60 mg to fimasartan 120 mg if siDBP was ≥90 mmHg. Results: Of the 263 randomized patients, 256 patients who had available efficacy data were analyzed. The fimasartan/HCTZ treatment group showed a greater reduction of siDBP compared to the fimasartan treatment group at Week 4 (6.88±8.10 mmHg vs 3.38±7.33, P=0.0008), and the effect persisted at Week 8 (8.67±9.39 mmHg vs 5.02±8.27 mmHg, P=0.0023). Reduction of sitting systolic BP in the fimasartan/HCTZ treatment group was also greater than that in the fimasartan treatment group (at Week 4, 10.50±13.76 mmHg vs 5.75±12.18 mmHg, P=0.0069 and, at Week 8, 13.45±15.15 mmHg vs 6.84±13.57 mmHg, P=0.0007). The proportion of patients who achieved a reduction of siDBP ≥10 mmHg from baseline and/or a mean siDBP <90 mmHg after 4 weeks of treatment was higher in the fimasartan/HCTZ treatment group than in the fimasartan treatment group (53.6% vs 39.8%, P=0.0359). The overall incidence of adverse drug reaction was 11.79% with no significant difference between the treatment groups. Conclusion: The combination treatment of fimasartan and HCTZ achieved better BP control than fimasartan monotherapy, and had comparable safety and tolerance to fimasartan monotherapy.

AB - Background: The study reported here compared the blood pressure (BP)-lowering efficacy of fimasartan alone with that of fimasartan/hydrochlorothiazide (HCTZ) combination in patients whose BP goal was not achieved after 4 weeks of treatment with once-daily fimasartan 60 mg. Methods: Patients with sitting diastolic blood pressure (siDBP) ≥90 mmHg with 4 weeks of once-daily fimasartan 60 mg were randomly assigned to receive either once-daily fimasartan 60 mg/HCTZ 12.5 mg or fimasartan 60 mg for 4 weeks. After 4 weeks, the dose was increased from fimasartan 60 mg/HCTZ 12.5 mg to fimasartan 120 mg/HCTZ 12.5 mg or from fimasartan 60 mg to fimasartan 120 mg if siDBP was ≥90 mmHg. Results: Of the 263 randomized patients, 256 patients who had available efficacy data were analyzed. The fimasartan/HCTZ treatment group showed a greater reduction of siDBP compared to the fimasartan treatment group at Week 4 (6.88±8.10 mmHg vs 3.38±7.33, P=0.0008), and the effect persisted at Week 8 (8.67±9.39 mmHg vs 5.02±8.27 mmHg, P=0.0023). Reduction of sitting systolic BP in the fimasartan/HCTZ treatment group was also greater than that in the fimasartan treatment group (at Week 4, 10.50±13.76 mmHg vs 5.75±12.18 mmHg, P=0.0069 and, at Week 8, 13.45±15.15 mmHg vs 6.84±13.57 mmHg, P=0.0007). The proportion of patients who achieved a reduction of siDBP ≥10 mmHg from baseline and/or a mean siDBP <90 mmHg after 4 weeks of treatment was higher in the fimasartan/HCTZ treatment group than in the fimasartan treatment group (53.6% vs 39.8%, P=0.0359). The overall incidence of adverse drug reaction was 11.79% with no significant difference between the treatment groups. Conclusion: The combination treatment of fimasartan and HCTZ achieved better BP control than fimasartan monotherapy, and had comparable safety and tolerance to fimasartan monotherapy.

KW - Angiotensin II type 1 receptor

KW - Angiotensin-converting enzyme inhibitor

KW - Angiotensin-receptor blocker

KW - Antihypertensive

KW - Blood pressure

KW - Renin–angiotensin–aldosterone system inhibitor

UR - http://www.scopus.com/inward/record.url?scp=84934956549&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84934956549&partnerID=8YFLogxK

U2 - 10.2147/DDDT.S82098

DO - 10.2147/DDDT.S82098

M3 - Article

VL - 9

SP - 2847

EP - 2854

JO - Drug Design, Development and Therapy

JF - Drug Design, Development and Therapy

SN - 1177-8881

ER -